Voluntis Announces Partnership with Tilak Healthcare to Help Patients with Cancer Better Manage Ocular Toxicities

Voluntis, an Aptar Pharma company and leader in digital therapeutics, today announced a partnership with Tilak Healthcare, a digital therapeutics company specializing in clinically validated medical mobile apps for chronic diseases. Under this new collaboration, both companies will combine Tilak’s OdySight® Care™ mobile app with Voluntis’ Theraxium platform to offer a vision-screening solution for patients living with cancer.

This new solution will give patients of Voluntis’ digital therapeutics (DTx) platform access to OdySight® Care™ and the possibility to measure their visual health anytime and anywhere. Once they have tested their vision using the OdySight® Care™ application on their mobile device, patients will receive a clinically-validated visual acuity score in real time, providing them with medical advice and guidance relating to their ophthalmic health.

Certain anti-cancer treatments such as chemotherapy or targeted immunotherapy are known for causing eye-related issues in some patients. Although ocular side effects such as a decrease in sharpness of vision may affect a patient’s quality of life and the ability to perform daily tasks such as reading or driving, most eye-related disorders caused by medical treatments can be managed with appropriate visual screening, monitoring or the adjustment of treatment doses. Therefore, this new integrated solution, which provides a digital testing tool for cancer patients to self-assess their visual acuity while undergoing treatment, may help improve patient care and could ultimately reduce the potential risk of treatment discontinuation.

“We welcome this new partnership with Voluntis to expand our solutions to new specialties, where visual acuity testing – thanks to the existing OdySight® platform, which now includes OdySight® Care™ – can help manage the follow-up of patients. It is a key milestone in our technology platform development and we are excited to provide visual acuity testing to patients through the Theraxium platform,” said Edouard Gasser, CEO, Tilak Healthcare

“We are pleased to announce our new collaboration with Tilak Healthcare, which will expand Theraxium’s capabilities and integrate our platform into a broader digital health ecosystem. This collaboration represents a new opportunity for patients to screen their visual acuity, and  access a better follow-up for their treatment-related symptoms,” added Pierre Leurent, CEO, Voluntis and President, Aptar Pharma Digital Health.

This new collaboration further underlines Voluntis’ vision to create a comprehensive ecosystem of sensors and digital biomarkers around its DTx platform. Through such partnerships, Voluntis will make these advanced capabilities available to its life sciences partners, offering adaptable, turnkey digital therapeutic solutions which aim to continuously improve the patient experience.

About Tilak Healthcare

Tilak  Healthcare is a unique mobile app studio where like-minded and passionate people create mobile medical apps for patients with chronic diseases. There is an ever-increasing demand for medical services, placing a huge burden on the healthcare system; doctors and caregivers need new, validated tools and resources to improve access. At Tilak Healthcare, every product on the market is clinically validated, developed with physician and patient advocates, compliant with medical device regulations, and protects the patient’s privacy. For more information, please visit http://www.tilakhealthcare.com/.

About Voluntis

Voluntis is an Aptar Pharma company and part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Voluntis creates digital therapeutics that empower people with chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Voluntis’ solutions combine mobile and web apps, using clinical algorithms to deliver personalized recommendations to patients and their care teams to adjust treatment dosage, manage side effects or monitor symptoms.

Leveraging its Theraxium technology platform, Voluntis designs digital therapeutics solutions across multiple areas, including oncology and diabetes. Based in Cambridge, MA, and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance. For more information, please visit: www.voluntis.com and www.aptar.com.